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KEY POINTS
 Patients with inflammatory bowel disease and dysplasia have pathologic characteristics
and risks that differ from those of patients with sporadic carcinomas.
 Surgical interventions need to be more aggressive than in sporadic cases.
 An algorithm for management strategies for lesions and strictures in Crohn’s disease and
ulcerative colitis needs to be developed.
 A better understanding of the risks and benefits of surgical procedures for dysplasia in
Crohn’s disease and ulcerative colitis is required.BACKGROUND
Colorectal cancer (CRC) arising in inflammatory bowel disease (IBD) accounts for only
1% to 2%of all general CRC cases per year. However, as CRC results in 15%of all IBD
deaths, cancer screening requires special vigilance in this group. Particularly
concerning is the fact that cancers in patients with ulcerative colitis and Crohn’s dis-
ease often present not asmass lesions but as dysplasia, strictures, or diffuse dysplasia.
The risk of CRC in ulcerative colitis (UC) has been well studied. Most reliable risk
factors associated with an increased risk of CRC in UC are related to the extent
and duration of the disease. The risk for CRC development is lower before 8 to 10 years
after onset of symptoms (3%); however, thereafter the risk increases by approximatelyRelationships: None.
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at 20 years of the disease.1–3 By the fourth decade of UC disease, the risk of devel-
oping CRC is as high as 56 times higher than that of the general population.4 In
2012, a large Danish population-based study demonstrated decreasing rates of
CRC in UC over the last 30 years. This decrease is due possibly to the improved med-
ical treatment of the disease in addition to surveillance of dysplasia.5
The rates of CRC in Crohn’s disease seem to mirror those of UC.6,7 Crohn’s patients
have a 5- to 20-fold increase in risk for CRC in comparison with the general popula-
tion.7,8 The absolute cumulative frequencies of CRC after 20 years of disease in
both UC and Crohn’s disease are similar at 8% and 7%, respectively.9 Because of
this similarity, despite the publication of fewer data regarding CRC in Crohn’s disease,
guidelines and recommendations have been developed for Crohn’s patients extrapo-
lating from the body of evidence on UC.
DYSPLASIA AS A PREDICTOR
The mutation pathway to CRC in IBD is postulated to be distinct from the adenoma-
carcinoma sequence seen in sporadic colon cancers. Duration and extent of disease
are both associated with higher rates of dysplasia and malignancy. IBD-associated
cancer often develops in younger patients, and is more likely to be diffuse, extensive,
multifocal, and mucinous, compared with the population with sporadic colorectal
cancer.10–12 Cancer in Crohn’s disease is more likely to be right-sided and associated
with ileal/right-sided inflammation.9
Furthermore, IBD patients with colon cancer have historically been shown to have
synchronous dysplasia at distant sites from the cancer, suggesting the potential for
a field defect rather than an isolated mutation. A review from more than 2 decades
ago that included 10 prospective studies with a total of 1225 UC patients demon-
strated cancer in 43% of patients with biopsy-proven high-grade dysplasia (HGD).
Nineteen percent of patients with low-grade dysplasia (LGD) also had a coexistent
cancer.13 Dysplasia distant to the primary carcinoma has also been shown in 23%
to 70% of patients with Crohn’s disease.8 Indeed, the reported risks of synchronous
lesions have been variable, as high as 71% for synchronous dysplasia and ranging
from 17% to 43% for synchronous cancers.13–19
Interpretation of the data on synchronous cancers should, however, be made with
caution, owing to the significant limitations during that era in the sensitivity of the fiber-
optic technology in detecting dysplasia or cancer at index colonoscopy. Furthermore,
surveillance of patients with dysplasia was not standardized (eg, performed without
chromoendoscopy or image enhancement at various intervals, or in the endoscopic
removal techniques). The true incidence of synchronous colorectal cancer in the
setting of dysplasia, as well as the true natural history of endoscopically invisible
dysplasia, is thus not known.
For high-risk patients the decision regarding whether to proceed with colectomy or
local endoscopic removal with continued colonoscopic surveillance is unquestionably
complex, and requires a multidisciplinary approach.
DYSPLASIA MANAGEMENT
Endoscopically Visible Dysplasia
Nowadays most IBD-related dysplasia visible, following the advancements of endo-
scopic imaging and techniques and a deeper understanding of its appearance, and
can be removed endoscopically. Furthermore, terminology for neoplasia in IBD is
now being standardized to be similar to neoplasia not related to IBD (ie, polypoid
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sectable for management). Historical terms such as adenoma-like dysplasia-associ-
ated lesion or mass (DALM) and non–adenoma-like DALM, or flat dysplasia, are
being abandoned because they are regarded as confusing, and conceived when
dysplasia was largely thought to be invisible during an era of lower-quality endoscopic
imaging and interpretation.
In fact, longitudinal studies show that isolated adenomatous polyps may be safely
removed endoscopically with close follow-up, analogous to sporadic adenoma
removal in the absence of colitis. Such adenomatous polyps treated with endoscopic
resection alone have been found to have no increased risk for cancer, as long as there
is no evidence of dysplasia in the mucosa surrounding the polyp or elsewhere in the
colon.20–22 Numerous biopsies of the region surrounding the area of concern are rec-
ommended in evaluating for dysplasia. If these biopsies are positive for dysplasia,
local or endoscopic resection is not recommended. A lesion that occurs proximally
to known areas of colitis without surrounding inflammation can be considered as
sporadic adenoma, and treated endoscopically.
Endoscopically Invisible or Nonresectable Dysplasia
Close involvement of the surgeon, gastroenterologist and pathologist in evaluating
dysplasia allows for the best management choices and optimal outcomes. This sec-
tion focuses on the surgical management of endoscopically invisible or nonresectable
dysplasia.
First, it is recommended that a diagnosis of dysplasia (LGD or HGD) be indepen-
dently confirmed by 2 experienced gastrointestinal pathologists. Controversy con-
tinues regarding the management of LGD, owing to the variation in reported rates of
progression from LGD to HGD or cancer.23 Patients confirmed to have endoscopically
invisible multifocal LGD or repetitive endoscopically invisible unifocal LGD following
evaluation by an expert endoscopist using chromoendoscopy should be counseled
and given a strong recommendation for total proctocolectomy.24 A decision analysis
for endoscopically invisible unifocal LGD compared cost-effectiveness of enhanced
surveillance with immediate colectomy, and found that immediate colectomy was
associated with higher quality-adjusted life years and lower costs.24 Nonetheless, pa-
tients with endoscopically invisible unifocal LGD on surveillance colonoscopy who do
not wish to undergo an operation should have the area tattooed, repeat surveillance
colonoscopy with chromoendoscopy performed at 3, 6, and 12 months with local
and distant biopsies, and then annually.
Before surgical intervention, any patient with a known dysplastic or cancerous le-
sions should undergo complete colonoscopy surveillance with chromoendoscopy,
which allows for best evaluation of where dysplasia may exist. If dysplasia remains
endoscopically invisible, a minimum of 3 biopsies every 10 cm is standard; in addition,
biopsies of the rectum and anal transition zone should be performed to rule out
dysplasia. Multiple biopsies should be performed in any transition zone where an
anastomosis may be considered. Surgical options will be based on these findings.
Surgical Options for Resection
Risks of recurrence of disease or findings of synchronous disease must be weighed
against the morbidity of surgical resection. Recommendations are generally varied
for Crohn’s disease and UC, and also vary based on type of dysplasia, morbidities,
and patient factors (Figs. 1 and 2).
Initial evaluation of patients includes assessment of overall medical stability, fitness
for surgery, and current function. Decisions for surgery must be based on the patient’s
Fig. 1. Surgical options for ulcerative colitis with dysplasia found on colonoscopy. IPAA, ileal
pouch anal anastomosis; IRA, ileorectal anastomosis; TAC, total abdominal colectomy; TPC,
total proctocolectomy.
Fig. 2. Surgical options for Crohn’s colitis with dysplasia found on colonoscopy.
Coviello & Stein450
Lesions and Strictures in Colonic IBD 451ability to undergo surgery; in some cases suboptimal procedures will be performed
secondary to limited preoperative life expectancy and anticipated comorbidities
from undergoing surgery. In addition, assessment of preoperative defecatory dysfunc-
tion including incidents of fecal incontinence should be evaluated. Patients with severe
preoperative incontinence and difficulty with mobility may benefit most from resection
with creation of stomas for functional reasons. Overall goals should be preservation of
the quality of life combined with appropriate oncologic resection.
The gold standard for patients from an oncologic perspective is total proctocolec-
tomy with perineal resection and end ileostomy. All colonic mucosa is removed, up to
and including mucosa at the anorectal junction, therefore virtually eliminating the risk
of colonic metaplasia and advancement to cancer. This result must be weighed
against the patient’s desire for intestinal continuity. Most patients would prefer to
have intestinal continuity, and complete removal of the rectoanal junction would leave
them with a permanent colostomy. In addition, though eliminating the risk of concur-
rent or future colon cancer, in patients with isolated disease or with sporadic adenoma
this may not be necessary from an oncologic perspective.
For patients with UC a total proctocolectomy with ileal pouch anal anastomosis is a
possibility. This operation removes the colon and colonic mucosa except a small
margin at the anorectal junction, and allows for replacement of the rectum with an ileal
pouch. The pouch serves as a reservoir to store stool and decrease frequency of
defecation for patients. The disadvantages of this procedure include a small risk of
recurrence within the rectal mucosa at the margin of the pouch, necessitating regular
surveillance; and complication rates of the surgery, which are often 15% or greater
and include risk of reoperation, incontinence, decreased fertility, and sexual dysfunc-
tion.25 Some patients with isolated Crohn’s colitis and no signs of small intestine or
perianal disease may also be appropriate for total proctocolectomy with ileal pouch
anal anastomosis These patients are at higher risk of pouch complications such as fis-
tulization, recurrence of pouch inflammation (pouchitis), and pouch failure. To
consider this procedure, patients must have good sphincter function at baseline, be
surgically fit, and not have signs of low rectal or anal dysplasia on screening biopsies.
If HGD is found in the rectum during colonoscopy, reconstruction with ileal pouch anal
anastomosis should be delayed to avoid the risk of radiation to the pouch if synchro-
nous advanced carcinoma is found within the rectum after surgical resection. Risks of
cancer in the retained rectal mucosa are generally low, reported as less than 5% at
25 years.26,27 A mucosectomy, or removal of the rectal mucosa down to the anorectal
ring, may be performed, but continence may be compromised in this case. In general,
patients are expected to have 4 to 6 bowel movements daily, and some soilage or
nighttime incontinence is not uncommon.
For patients with diffuse colonic disease but without rectal involvement, it may also
be possible to consider a total abdominal colectomy with ileal rectal anastomosis.
Advantages of this operation generally include preserved rectal and sexual function.
The operation itself is shorter and less extensive. However, this operation does not
treat dysplasia or inflammatory disease within the rectum. This area will require
continued surveillance, and in patients with both Crohn’s disease and UC the rates
of recurrence of inflammatory disease in the rectum are as high as 60%.28 This oper-
ation is contraindicated in patients with rectal or anal lesions, and considered as very
high risk for patients with multifocal dysplasia. Other contraindications include pa-
tients with baseline fecal incontinence or severe rectal inflammation.
For patients who are not fit for anastomosis, or reconnection, a total abdominal
colectomy with Hartmann procedure may be performed. This operation leaves the
remnant rectum in place during the operation, and an end ileostomy is performed.
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rectum in situ. However, risks include inflammation and risk of dysplasia within the
rectum, and continued surveillance is necessary.
In isolated inflammatory and dysplastic disease, or in cases of a sporadic adenoma,
the most appropriate operation may be a segmental colectomy. Benefits of this oper-
ation include shorter operative times, maintenance of key portions of the colon,
including possibly the ileocecal valve which may functionally decrease risks of diar-
rhea, and the greater part of the colon for fluid absorption. This option is restricted
to patients with isolated dysplasia and those with relatively normal mucosa in terms
of inflammation; surgical anastomosis necessitates functional mucosa for creation
of a colon anastomosis. Patients who undergo this option must be committed to
continued colonoscopic surveillance to evaluate for metachronous lesions and the
risk of continued progression of inflammatory disease. Data demonstrate that up to
40% of patients with Crohn’s disease will require additional colectomy at 10 years
for recurrence of inflammation after segmental colectomy.29,30
All resections, whether segmental or complete proctocolectomies, should follow the
principles of surgical oncology. A full lymphadenectomy and vessel resection with high
ligation should be completed. Current data recommend resection of a minimum of 12
lymph nodes for segmental colectomy to ensure appropriate staging of tumors.31
In addition, good data also exist to affirm that the use of laparoscopic or minimally
invasive surgery is beneficial for patients.32 All of the aforementioned procedures can
be performed laparoscopically in experienced hands. Contraindications to laparo-
scopic surgery are few and decreasing in number, but may include extensive prior
adhesions, bulky mesentery, and extraluminal invasion. Benefits of laparoscopy
include decreased postoperative pain and quicker return to function; moreover, lapa-
roscopy may allow appropriate patients earlier access to definitive medical oncology
treatments.STRICTURES
The repeated cycle of inflammation, necrosis, and ulceration, alternating with the
deposition of granulation tissue during the healing phase, results in the development
of raised areas of inflamed tissue that resemble polyps, called pseudopolyps, or may
result in stricture formation. Such sequelaemake endoscopic surveillance of dysplasia
and cancer, and its management, a challenge.
Colonic strictures are more common in Crohn’s disease than in UC. Colonic stric-
tures reportedly are found in 5% to 17% of patients with Crohn’s colitis.10 Although
data are lacking, colonic strictures have been reported in approximately 5% of UC pa-
tients. Rates of stricture occurrence seem to be improving as medical treatments
allow more patients to achieve remission. Colonic strictures in any setting should be
considered malignant until proven otherwise. Gumaste and colleagues33 evaluated
the Mount Sinai Hospital (New York) population of UC patients with strictures, and
found 29% to be malignant. In Crohn’s disease, despite a higher rate of stricture
occurrence, the rate of malignant colorectal strictures was only 6.8%.34 There is no
role for stricturoplasty in the primary management of colonic strictures in IBD. Stric-
tures found at prior anastomotic sites in Crohn’s disease may be judiciously dilated
to allow for endoscopic evaluation of recurrence or technical problems from the orig-
inal resection. Dysplasia and carcinoma at colonic strictures cannot always be
detected preoperatively.35 The stricture must be able to be traversed, adequately
examined, and biopsied. Even then, the risk of sampling error in a stricture can be
high; a biopsied portion may demonstrate inflammation and fail to show deeper
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UC, proctocolectomy is the only means to definitively diagnose or rule out carcinoma
and to treat possible multifocal malignancy, and should be considered in the manage-
ment of colonic UC stricture. Unlike UC, a segmental oncologic resection may be
appropriate in Crohn’s disease colorectal stricture in a patient with limited segmental
disease.
SUMMARY
Identification and treatment of dysplasia and colorectal cancer in IBD creates
management challenges for the clinician. Treatment options for patients must be
based on the understanding of differences in virulence between sporadic adenomas
and inflammatory related dysplasia in patients with IBD. Surgical interventions should
be based on patient morbidities, location and type of inflammation, and, most impor-
tantly, findings of dysplasia. Although the gold standard for oncologic resection is total
proctocolectomy, many appropriate options exist that allow for intestinal continuity.
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